Developer docs
API playgroundTry for free, no card

Search company profiles

KIZOO Technology Capital

Full company profile

uuid0005pr3

Namestring
KIZOO Technology Capital
Legal namestring
KIZOO Technology Capital GmbH
Websiteurl
kizoo.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

KIZOO Technology Capital GmbH is a privately held venture capital firm headquartered in Karlsruhe, Germany, founded in 2000 as part of the Mira Holding group. The firm specializes in seed and early-stage investments in rejuvenation and longevity biotechnology, targeting startups that develop therapies addressing the root causes of aging rather than individual age-related diseases. Its active portfolio comprises six companies — Reservoir Neuroscience (vascular rejuvenation of the aging brain), Cyclarity (arterial plaque clearance), Elastrin (anti-calcification therapeutics), Revel Pharmaceuticals (collagen crosslink-breaking drugs), MoglingBio (hematopoietic stem cell rejuvenation via CDC42 modulation), and Cellvie (Therapeutic Mitochondria Transfer for ischemia-reperfusion injury) — each backed by academic research from institutions including Harvard, Yale, UC Berkeley, Clemson, and the SENS Research Foundation.

KIZOO's investment activities are tightly integrated with its sister organization Forever Healthy Foundation under the Mira Holding umbrella, creating a vertically aligned pipeline from basic research co-funding through to commercial biotech deployment. The firm also retains legacy equity positions in German internet and SaaS unicorns including Babbel, Mambu, Staffbase, and MOQO, though it has explicitly exited new investment activity in that sector. The operating model is highly concentrated — 1-10 employees, undisclosed capital deployment amounts, and a thesis-driven six-portfolio strategy — with returns generated through equity appreciation and exit events rather than external LP management fees.

Short descriptiontext

KIZOO Technology Capital is a Karlsruhe-based micro-VC that seeds and mentors early-stage rejuvenation biotechnology startups, deploying capital into a concentrated six-company portfolio that targets the root cellular causes of aging under the Mira Holding group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKarlsruhe, Germany
HQ citystring
Karlsruhe
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, rejuvenation biotechnology, longevity biotech funding, seed stage financing, early stage biotech
NAICS code1 code
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
Product category
Venture Capital / Rejuvenation Biotech Investment
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

KIZOO generates returns through equity investments in portfolio companies. As a VC firm, returns come from capital appreciation, exit events (IPOs, acquisitions), and carried interest on successful investments in the longevity and rejuvenation biotechnology sector.

kizoo.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KIZOO Technology Capital is a venture capital firm that provides seed and early-stage financing, plus mentoring, to startups developing rejuvenation and longevity biotechnology. It invests in never-done-before technologies targeting the root causes of aging — including molecular waste accumulation, calcification, tissue stiffening, stem cell loss, genetic alterations, and impaired energy production — while also retaining legacy minority stakes in German internet and SaaS unicorns.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Targeting prevention and reversal of age-related diseases including atherosclerosis, heart attack, stroke, neurodegeneration, leukemia, and blood diseases
Product overview1 text field

KIZOO Technology Capital is a venture capital firm that invests in rejuvenation and longevity biotechnology companies. As part of Mira Holding and complementing the mission of its sister organization Forever Healthy, KIZOO deploys capital into early-stage biotech startups developing therapies targeting the root causes of aging. The firm also maintains legacy investments in internet and SaaS companies including Staffbase, Mambu, Moqo, and Babbel, though no new investments are being made in that sector.

Product and service2 records
1Seed and Early-Stage Equity Financing (Rejuvenation Biotech)
CategoryVenture Capital Investment Services
Description

Seed and early-stage equity capital, plus mentoring, provided to startups developing rejuvenation and longevity biotechnologies that target the root causes of aging. Customers are founders of early-stage biotech companies.

2Legacy Internet & SaaS Equity Stakes
CategoryLegacy Equity Investments
Description

Existing minority shareholdings retained in German internet and SaaS unicorns including Staffbase, Mambu, MOQO, and Babbel. No new investments are being made in this sector.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Mira Holding
Strategic tierCoreTypeStrategic or Co-development Partner
Description

KIZOO is part of Mira Holding, which owns and manages the company's biotech investment activities. This parent structure provides strategic alignment and organizational support for KIZOO's investment operations.

kizoo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Forever Healthy is KIZOO's sister organization within the Mira Holding ecosystem. The organizations complement each other's missions, with Forever Healthy focused on research and KIZOO focused on investment in rejuvenation biotechnology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research foundation that has co-funded and supported development of basic technologies for portfolio companies Cyclarity and Revel Pharmaceuticals. Represents scientific ecosystem connection.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Foundation that has funded basic technology development for portfolio companies Cyclarity and Revel Pharmaceuticals, demonstrating collaborative approach to advancing rejuvenation biotechnology research.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Switzerland/Malta-based venture firm dedicated to accelerating longevity and regenerative medicine breakthroughs from lab to clinic. Like KIZOO, it pursues early-stage, science-driven biotech bets focused on extending healthy human lifespan.

TypeBroad incumbent
Description

Deep-tech venture firm with notable investments in biology, longevity-adjacent biotech, and frontier science. It shares KIZOO's appetite for science-heavy, unconventional bets but operates at meaningfully larger fund sizes.

TypeBroad incumbent
Description

a16z's bio/health fund has made dedicated bets on longevity and computational biology alongside its broader biotech mandate. It represents a scaled incumbent competing for the same high-quality longevity deals KIZOO pursues.

TypeEmerging player
Description

Early-stage fund with portfolio exposure to longevity and transformative-life-extension companies. It intersects KIZOO's thesis on emerging biomedical frontiers while remaining a smaller, more thematically diffuse player.

TypeBroad incumbent
Description

Specialist deep-science/early-stage biotech investor building companies from breakthrough academic research, comparable in its comfort with pre-clinical biotech risk but operating with much larger capital pools than KIZOO.

TypeBroad incumbent
Description

Large US venture firm that has publicly invested in longevity-adjacent biotech (and was named alongside KIZOO as one of 8 active longevity VCs). It covers a much broader mandate across tech and bio, serving as a benchmark incumbent rather than a direct competitor for niche deals.

TypeBroad incumbent
Description

Tim Draper's early-stage venture firm identified as one of 8 VCs actively investing in longevity. It deploys generalist seed capital with selected exposure to longevity biotech, comparable in stage but not thematic focus.

TypeDirect peer
Description

Berlin-based early-stage VC specializing in longevity and rejuvenation biotechnology with a comparable academic-spinout investment thesis. Apollo is one of the few European funds operating in the same niche, making it the closest direct peer to KIZOO's mandate and deal profile.

TypeDirect peer
Description

US-based seed-to-Series A investor exclusively focused on aging biology and longevity therapeutics. It targets the same early-stage, science-driven rejuvenation biotech companies as KIZOO, making it a near-comparable peer on stage and sector.

TypeDirect peer
Description

Investment vehicle backing early-stage companies in longevity and preventive medicine, named alongside KIZOO as one of the 8 active VCs in the longevity sector. It shares KIZOO's thematic focus on therapies that target age-related disease drivers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment49 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KIZOO Technology Capital

Venture Capital / Rejuvenation Biotech Investmentkizoo.com

KIZOO Technology Capital is a Karlsruhe-based micro-VC that seeds and mentors early-stage rejuvenation biotechnology startups, deploying capital into a concentrated six-company portfolio that targets the root cellular causes of aging under the Mira Holding group.

What KIZOO Technology Capital does

KIZOO Technology Capital GmbH is a privately held venture capital firm headquartered in Karlsruhe, Germany, founded in 2000 as part of the Mira Holding group. The firm specializes in seed and early-stage investments in rejuvenation and longevity biotechnology, targeting startups that develop therapies addressing the root causes of aging rather than individual age-related diseases. Its active portfolio comprises six companies — Reservoir Neuroscience (vascular rejuvenation of the aging brain), Cyclarity (arterial plaque clearance), Elastrin (anti-calcification therapeutics), Revel Pharmaceuticals (collagen crosslink-breaking drugs), MoglingBio (hematopoietic stem cell rejuvenation via CDC42 modulation), and Cellvie (Therapeutic Mitochondria Transfer for ischemia-reperfusion injury) — each backed by academic research from institutions including Harvard, Yale, UC Berkeley, Clemson, and the SENS Research Foundation.

KIZOO's investment activities are tightly integrated with its sister organization Forever Healthy Foundation under the Mira Holding umbrella, creating a vertically aligned pipeline from basic research co-funding through to commercial biotech deployment. The firm also retains legacy equity positions in German internet and SaaS unicorns including Babbel, Mambu, Staffbase, and MOQO, though it has explicitly exited new investment activity in that sector. The operating model is highly concentrated — 1-10 employees, undisclosed capital deployment amounts, and a thesis-driven six-portfolio strategy — with returns generated through equity appreciation and exit events rather than external LP management fees.

KIZOO Technology Capital firmographics

Firmographics
Name
KIZOO Technology Capital
Legal name
KIZOO Technology Capital GmbH
Website
https://kizoo.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
KIZOO Technology Capital is a Karlsruhe-based micro-VC that seeds and mentors early-stage rejuvenation biotechnology startups, deploying capital into a concentrated six-company portfolio that targets the root cellular causes of aging under the Mira Holding group.
Ownership category
akta.pro rank

Where KIZOO Technology Capital is headquartered

Location

Headquarters

HQ city
Karlsruhe
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

KIZOO Technology Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Venture Capital Returns: KIZOO generates returns through equity investments in portfolio companies. As a VC firm, returns come from capital appreciation, exit events (IPOs, acquisitions), and carried interest on successful investments in the longevity and rejuvenation biotechnology sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

KIZOO Technology Capital product offering

Product offering

Core offering

KIZOO Technology Capital is a venture capital firm that provides seed and early-stage financing, plus mentoring, to startups developing rejuvenation and longevity biotechnology. It invests in never-done-before technologies targeting the root causes of aging — including molecular waste accumulation, calcification, tissue stiffening, stem cell loss, genetic alterations, and impaired energy production — while also retaining legacy minority stakes in German internet and SaaS unicorns.

Product overview

KIZOO Technology Capital is a venture capital firm that invests in rejuvenation and longevity biotechnology companies. As part of Mira Holding and complementing the mission of its sister organization Forever Healthy, KIZOO deploys capital into early-stage biotech startups developing therapies targeting the root causes of aging. The firm also maintains legacy investments in internet and SaaS companies including Staffbase, Mambu, Moqo, and Babbel, though no new investments are being made in that sector.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seed and Early-Stage Equity Financing (Rejuvenation Biotech) Seed and early-stage equity capital, plus mentoring, provided to startups developing rejuvenation and longevity biotechnologies that target the root causes of aging. Customers are founders of early-stage biotech companies.
  • Legacy Internet & SaaS Equity Stakes Existing minority shareholdings retained in German internet and SaaS unicorns including Staffbase, Mambu, MOQO, and Babbel. No new investments are being made in this sector.

Quantifiable outcome

  • Targeting prevention and reversal of age-related diseases including atherosclerosis, heart attack, stroke, neurodegeneration, leukemia, and blood diseases

Companies that use KIZOO Technology Capital

Customer profile

Segments1 record

Ideal customer profiles1 record

KIZOO Technology Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

KIZOO Technology Capital partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Mira HoldingcoreStrategic or Co-development PartnerKIZOO is part of Mira Holding, which owns and manages the company's biotech investment activities. This parent structure provides strategic alignment and organizational support for KIZOO's investment operations.
  • Forever HealthycoreStrategic or Co-development PartnerForever Healthy is KIZOO's sister organization within the Mira Holding ecosystem. The organizations complement each other's missions, with Forever Healthy focused on research and KIZOO focused on investment in rejuvenation biotechnology.
  • SENS Research FoundationminorStrategic or Co-development PartnerResearch foundation that has co-funded and supported development of basic technologies for portfolio companies Cyclarity and Revel Pharmaceuticals. Represents scientific ecosystem connection.
  • Forever Healthy FoundationminorStrategic or Co-development PartnerFoundation that has funded basic technology development for portfolio companies Cyclarity and Revel Pharmaceuticals, demonstrating collaborative approach to advancing rejuvenation biotechnology research.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

KIZOO Technology Capital competitors and assessment

Company assessment

Direct peers

  • LongeVC: Switzerland/Malta-based venture firm dedicated to accelerating longevity and regenerative medicine breakthroughs from lab to clinic. Like KIZOO, it pursues early-stage, science-driven biotech bets focused on extending healthy human lifespan.
  • Apollo Health Ventures: Berlin-based early-stage VC specializing in longevity and rejuvenation biotechnology with a comparable academic-spinout investment thesis. Apollo is one of the few European funds operating in the same niche, making it the closest direct peer to KIZOO's mandate and deal profile.
  • age1: US-based seed-to-Series A investor exclusively focused on aging biology and longevity therapeutics. It targets the same early-stage, science-driven rejuvenation biotech companies as KIZOO, making it a near-comparable peer on stage and sector.
  • Longevity Vision Holding: Investment vehicle backing early-stage companies in longevity and preventive medicine, named alongside KIZOO as one of the 8 active VCs in the longevity sector. It shares KIZOO's thematic focus on therapies that target age-related disease drivers.

Broad incumbents

  • Lux Capital: Deep-tech venture firm with notable investments in biology, longevity-adjacent biotech, and frontier science. It shares KIZOO's appetite for science-heavy, unconventional bets but operates at meaningfully larger fund sizes.
  • Andreessen Horowitz (a16z Bio): a16z's bio/health fund has made dedicated bets on longevity and computational biology alongside its broader biotech mandate. It represents a scaled incumbent competing for the same high-quality longevity deals KIZOO pursues.
  • ARCH Venture Partners: Specialist deep-science/early-stage biotech investor building companies from breakthrough academic research, comparable in its comfort with pre-clinical biotech risk but operating with much larger capital pools than KIZOO.
  • Khosla Ventures: Large US venture firm that has publicly invested in longevity-adjacent biotech (and was named alongside KIZOO as one of 8 active longevity VCs). It covers a much broader mandate across tech and bio, serving as a benchmark incumbent rather than a direct competitor for niche deals.
  • Draper Associates: Tim Draper's early-stage venture firm identified as one of 8 VCs actively investing in longevity. It deploys generalist seed capital with selected exposure to longevity biotech, comparable in stage but not thematic focus.

Emerging players

  • BOLD Capital Partners: Early-stage fund with portfolio exposure to longevity and transformative-life-extension companies. It intersects KIZOO's thesis on emerging biomedical frontiers while remaining a smaller, more thematically diffuse player.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

KIZOO Technology Capital social profiles

Digital presence

KIZOO Technology Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KIZOO Technology Capital leadership team

Management profile

Number of profiles

Profiles4 records

KIZOO Technology Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KIZOO Technology Capital M&A and investment

M&A and investment

M&A

Investments49 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KIZOO Technology Capital

What does KIZOO Technology Capital do?

KIZOO Technology Capital is a venture capital firm that provides seed and early-stage financing, plus mentoring, to startups developing rejuvenation and longevity biotechnology. It invests in never-done-before technologies targeting the root causes of aging — including molecular waste accumulation, calcification, tissue stiffening, stem cell loss, genetic alterations, and impaired energy production — while also retaining legacy minority stakes in German internet and SaaS unicorns.

Is KIZOO Technology Capital a public or private company?

KIZOO Technology Capital is a private company. It is classified as corporate owned and is currently operating.

When was KIZOO Technology Capital founded?

KIZOO Technology Capital was founded in 2000. It employs 1 to 10 people.

Where is KIZOO Technology Capital based?

KIZOO Technology Capital is headquartered in Karlsruhe, Germany, in the Europe region.

How does KIZOO Technology Capital make money?

One revenue line is on record: venture Capital Returns.

Who are KIZOO Technology Capital's main competitors?

Direct peers on record are LongeVC, Apollo Health Ventures, age1 and Longevity Vision Holding. Broad incumbents are Lux Capital, Andreessen Horowitz (a16z Bio), ARCH Venture Partners, Khosla Ventures and Draper Associates. BOLD Capital Partners is listed as an emerging player.

Does KIZOO Technology Capital have an API?

No public API is recorded for KIZOO Technology Capital.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEscellvie Raises $5.5M in Financingcellvie Inc. closed a $5.5 million financing round led by Taiho Ventures, with participation from existing investor Kizoo Technology Capital GmbH. The company plans to utilize the funds to accelerate its Therapeutic Mitochondria Transplantation technology platform and expand manufacturing capabilities.PR NewswireHarvard spin-off CELLVIE raises $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modalityHarvard spin-off cellvie Inc. has secured an additional $5.5 million in funding led by Taiho Ventures LLC to accelerate the development of its Therapeutic Mitochondria Transplantation technology. The company intends to use this capital to prepare for a Series A round by the end of 2023, expand its research into applications like gene therapy and aging, and strengthen its manufacturing capabilities. This investment reinforces the backing of existing investor Kizoo Technology Capital, which also participated in the round.FinSMEsMogling Bio Receives Seed Investment from Kizoo Technology CapitalMogling Bio, a biotech company based in Germany, has received seed investment from Kizoo Technology Capital. The undisclosed funds will be utilized to expand operations and development efforts for its pharmacological approaches targeting stem cell rejuvenation. The technology underlying these treatments was developed over 15 years by the company's scientific co-founders.GlobeNewswireKizoo Portfolio Company Underdog Closes $10M Financing RoundUnderdog Pharmaceuticals closed a $10 million Series Seed II round led by Kizoo, with participation from existing and new investors. The company's compound UDP-003 targets oxidized cholesterol to prevent heart attacks and strokes, and it expects to begin clinical trials in 2023.GlobeNewswireKizoo Portfolio Company Underdog Closes $10M Financing RoundUnderdog Pharmaceuticals has closed a $10 million Series Seed II financing round led by Kizoo Technology Capital. The funding supports the development of UDP-003, a synthetic compound designed to treat cardiovascular disease by targeting oxidized cholesterol. This investment follows the company's recent award of an Innovation Passport under the UK's ILAP framework, enabling faster patient access and anticipated clinical trials in 2023.BioWorldKizoo to invest $362M in ‘rejuvenation biotech’Michael Greve is committing €300 million (US$362 million) to a portfolio of rejuvenation biotech firms via Kizoo Technology Capital GmbH. The investment vehicle has already provided seed funding to over a dozen early-stage firms and is now ready for follow-on rounds in four core companies.GlobeNewswireNovel therapeutic approach to cardiovascular disease fromUnderdog Pharmaceuticals and SENS Research Foundation announced the launch of Underdog and its seed round, raising $3.95 million led by Kizoo Technology Capital. The funding will support development of disease-modifying treatments for atherosclerosis and other age-related diseases. SRF also appointed Alexandra Stolzing as VP of Research and Jim O'Neill as interim CEO.SENS Research FoundationLifespan Research InstituteLifespan Research Institute aims to extend healthy human lifespan by addressing aging's root causes, supporting research, education, investment, and advocacy. It highlights recent studies on senolytic vaccines and senescent cell targeting, and notes a CEO preprint on public support for longevity.CNETOnline language tools lure German venture firmsBabbel raised its first financing round from German venture firms Kizoo and VC Fonds. The company, part of Lesson Nine, plans to expand with new grammar lessons for basic to intermediate levels. The amount raised was not disclosed, but a source said it was in the hundreds of thousands of dollars.